Rapamycin and mTORC1 Inhibition in the Mouse: Skin Cancer Prevention

被引：24
作者：
Athar, Mohammad [1 ,2 ]
Kopelovich, Levy [3 ]
机构：
[1] Univ Alabama Birmingham, Dept Dermatol, Skin Dis Res Ctr, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA
[3] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
来源：
CANCER PREVENTION RESEARCH | 2011年 / 4卷 / 07期
关键词：
MAMMALIAN TARGET; MOTIF PHOSPHORYLATION; MODEL; AKT; ACTIVATION; GROWTH; MICE; CARCINOGENESIS; TUMORIGENESIS; PROGRESSION;
D O I：
10.1158/1940-6207.CAPR-11-0266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Therapeutic and preventive effects of rapamycin include reduced risk of nonmelanoma skin cancer (NMSC). In this issue of the journal (beginning on page 1011), Checkley and colleagues report that rapamycin inhibits mTOR complex 1 in murine epidermis, thereby inhibiting tumor promotion mediated by tetradecanoyl phorbol-13 acetate in association with a strong anti-inflammatory effect. Rapamycin is an immunosuppressive drug for preventing graft rejection in organ transplant recipients and reduces the risk of NMSC and Kaposi's sarcoma in this population, albeit by mechanisms distinct from immunosuppression. Important future directions include identifying molecular predictors of rapamycin/ rapalog sensitivity or resistance (potentially, for example, PI3K pathway alterations and KRAS mutations) and combined nonrapalog, mTOR-targeting approaches, all of which should increase efficacy and minimize toxicity. Cancer Prev Res; 4(7); 957-61. (C)2011 AACR.
引用
收藏
页码：957 / 961
页数：5
相关论文
共 57 条
[1]   Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe [J].
Aggarwal, Bharat B. ;
Vijayalekshmi, R. V. ;
Sung, Bokyung .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :425-430
[2]   Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck [J].
Amornphimoltham, P ;
Patel, V ;
Sodhi, A ;
Nikitakis, NG ;
Sauk, JJ ;
Sausville, EA ;
Molinolo, AA ;
Gutkind, JS .
CANCER RESEARCH, 2005, 65 (21) :9953-9961
[3]   Inhibition of Mammalian Target of Rapamycin by Rapamycin Causes the Regression of Carcinogen-induced Skin Tumor Lesions [J].
Amornphimoltham, Panomwat ;
Leelahavanichkul, Kantima ;
Molinolo, Alfredo ;
Patel, Vyomesh ;
Gutkind, J. Silvio .
CLINICAL CANCER RESEARCH, 2008, 14 (24) :8094-8101
[4]   Pathogenesis of nonmelanoma skin cancers in organ transplant recipients [J].
Athar, Mohammad ;
Walsh, Stephanie B. ;
Kopelovich, Levy ;
Elmets, Craig A. .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2011, 508 (02) :159-163
[5]   Oxidative stress in the pathogenesis of skin disease [J].
Bickers, David R. ;
Athar, Mohammad .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (12) :2565-2575
[6]   PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth [J].
Blando, Jorge ;
Portis, Melisa ;
Benavides, Fernando ;
Alexander, Angela ;
Mills, Gordon ;
Dave, Bhuvanesh ;
Conti, Claudio J. ;
Kim, Jeri ;
Walker, Cheryl Lyn .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (05) :1869-1879
[7]   Rapamycin Is a Potent Inhibitor of Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate [J].
Checkley, L. Allyson ;
Rho, Okkyung ;
Moore, Tricia ;
Hursting, Steve ;
DiGiovanni, John .
CANCER PREVENTION RESEARCH, 2011, 4 (07) :1011-1020
[8]   Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model [J].
Czeminski, Rakefet ;
Amornphimoltham, Panomwat ;
Patel, Vyomesh ;
Molinolo, Alfredo A. ;
Gutkind, J. Silvio .
CANCER PREVENTION RESEARCH, 2009, 2 (01) :27-36
[9]  
de Gruiji Frank R., 2009, V146, P101, DOI 10.1007/978-0-387-78574-5_9
[10]   Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis [J].
de Gruijl, F. R. ;
Koehl, G. E. ;
Voskamp, P. ;
Strik, A. ;
Rebel, H. G. ;
Gaumann, A. ;
de Fijter, J. W. ;
Tensen, C. P. ;
Bavinck, J. N. Bouwes ;
Geissler, E. K. .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (04) :796-804
123456